pentobarbital decreases effects of sufentanil SL by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Coadministration of CYP3A4 inducers may possibly minimize sufentanil ranges and efficacy, maybe precipitating withdrawal syndrome in sufferers who have designed physical dependence to sufentanil. Discontinuation